Until the companies say something more, I'll happily focus

New Post Public Reply Private Reply Replies (2) Message Board
grow lovindollars #61877
853
Until the companies say something more, I'll happily focus at first on what they have already said. When I research it, to me this looks like licenses per device at the merchants. So count up the # small and medium merchants, and look up the cost of the keystroke encryption annual license pricing & royalty rates between SFOR and CSI (ACS) on their SEC documents...

I say this because people should realize what CyberIDLock is. It is what this deal is about:
Keystroke Encryption
Dark Web scanning
and more
https://www.cyberidlock.com/
https://www.cyberidlock.com/for-business
https://www.advancedcybersecurity.com/

The recent SFOR press release says that the CyberIDLock bundle is embedded with their (SMB) PCI Security Solution of the worlds largest credit-card processor and will be distributed to millions of merchants in this deal. They then link to an ACS press release that shows that this deal is with First Data . They also mention that ACS has two additional merchant providers that also closed and will be launching by the end of January 2020. Each of those providers also have several millions of their own merchants.
https://www.globenewswire.com/news-release/20...ed-in.html

Here is a very rough summary of some figures supported by the links below. It's a start to research. There is no guarantee that this DD is accurate or relevant. Everyone should do their own research, make their own conclusions, and everyone should take responsibility for their own financial decisions.

6m + 3m + 3m merchants (not all are small and medium size)
at least $9.99 to license the keystroke encryption per year per device
15% royalty to SFOR at present, half of that after CSI pays for the related patents

size of First Data
https://investors.fiserv.com/static-files/084...3834a3c702

size of other 2 merchant providers
https://www.globenewswire.com/news-release/20...ed-in.html

CSI (ACS) deal with SFOR
https://www.sec.gov/Archives/edgar/data/12855...-index.htm


There are no guarantees.
.
.
.
.
.
.

Zerify Inc (ZRFY) Stock Research Links

ZRFY Board Company Profile Buy Rating Time & Sales News Filings Financials
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Hyzon Motors Plans Delisting from Nasdaq—What This Means

Updated Category News Views 195

Hyzon Motors Announces Delisting from Nasdaq Hyzon Motors Inc. is making a significant shift regarding its stock trading status. This U.S. company, known for its commitment to high-performance hydrogen fuel cell technology, has decided to inform Nasdaq Stock Market of its intent to delist its Class A common stock and publicly traded warrants. This move comes as part of...

Continue Reading
Unlock the Potential of Crypto Staking with Keynode.net

Updated Category News Views 113

Your Gateway to High Returns in Crypto Staking As the digital currency landscape continues to expand, platforms like Keynode.net are leading the charge in offering unprecedented opportunities for investors. For those seeking impressive annual percentage yields (APY) through crypto staking, Keynode.net has emerged as a premier choice. Its user-friendly interface, robust...

Continue Reading
Critical Updates for Rocket Pharmaceuticals Investors Amid Lawsuit

Updated Category News Views 263

Overview of the Class Action Lawsuit Against Rocket Pharmaceuticals Pomerantz LLP has initiated a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) highlighting various concerns regarding the company's business practices. Investors who have suffered losses during the stipulated Class Period should take note of this unfolding situation. Key Details...

Continue Reading
Revitalizing Economic Growth at the 23rd SMDO Conference

Updated Category News Views 141

Revitalizing Economic Growth at the 23rd SMDO Conference The 23rd Annual South Metro Development Outlook (SMDO25) Conference stands as a pivotal forum for industry leaders, policymakers, and community stakeholders. It is designed to foster collaboration and tackle some of the most pressing issues faced by the region today. Set against the backdrop of changing federal...

Continue Reading
SciBase's Strong Growth in Q1 2025: Key Highlights and Future

Updated Category News Views 222

Strong First Quarter Results for SciBase In the recent interim report, SciBase has showcased an impressive performance for the first quarter of 2025. The medical technology company, renowned for its innovative dermatological solutions, recorded net sales of TSEK 8,856, marking a remarkable increase of 46% from the previous year’s figures. Financial Performance Overview...

Continue Reading